A case of insulinoma with hypoglycemia that was better managed with lanreotide than octreotide

Long‐acting somatostatin analogs, including lanreotide slow release (LAN‐SR) and octreotide long‐acting release (OCT‐LAR), can improve hypoglycemia in insulinoma. LAN‐SR may be more beneficial in some patients with insulinoma than OCT‐LAR.

Detalles Bibliográficos
Autores principales: Yamaoka, Keiko, Nagashima, Shuichi, Okada, Nobukazu, Sawayama, Nagisa, Saito, Shinsuke, Takahashi, Manabu, Okada, Kenta, Endo, Kazuhiro, Koizumi, Masaru, Sasanuma, Hideki, Ebihara, Ken, Kasajima, Atsuko, Fukushima, Noriyoshi, Sata, Naohiro, Ishibashi, Shun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8133073/
https://www.ncbi.nlm.nih.gov/pubmed/34026158
http://dx.doi.org/10.1002/ccr3.4118

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8133073/
https://www.ncbi.nlm.nih.gov/pubmed/34026158
http://dx.doi.org/10.1002/ccr3.4118

Ejemplares similares